Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: ahhaha who wrote (250)	6/24/1998 12:25:00 AM
From: VikingWarrior	Read Replies (2) \| Respond to of 399

Your presentation on what not to buy has been most interesting. Is there an example of what you believe should be bought at this juncture and the reasons why? Thank you for your thoughts. Dave Martinson

To: ahhaha who wrote (250)	6/24/1998 3:12:00 AM
From: Rio Jangada	Read Replies (1) \| Respond to of 399

Confidence in ArQule portfolio of proprietary compounds and technology, their knowhow and management remain exceedingly high among 25 collaborators and partners. These are companies that are committing expertise and resources, pooling interests, and are enjoined for more than just a short while, as opposed to those shuffling around other people's money. A major drug company took a $5 million stake just this month. ArQule will have committed investors, advocates, cheerleaders, etc. for years to come. Panicky short-sighted investors and perhaps a few demoralized, distrusting, self-limited graphmakers have provided a tremendous buying opportunity here. Good riddance to them and welcome to the likes of Wyeth-Ayerst and the biotech-savy fella that publicly declared his faith by taking a >5% stake just a few days ago. Rio